Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma

Serine‐227 in the N‐terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma

Abstract RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK signaling pathway and may be a therapeutic target in mantle cell lymphoma (MCL), an almost incurable disease subtype of non‐Hodgkin lymphoma. In this study, serine‐227 (RSK2Ser227) in the N‐terminal kinase domain...

Full description

Bibliographic Details
Main Authors: Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yuji Shimura, Yoshiaki Chinen, Kazuna Tanba, Saeko Kuwahara‐Ota, Yuto Fujibayashi, Daichi Nishiyama, Reiko Isa, Junko Yamaguchi, Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
B cell tumorigenesis
mantle cell lymphoma
molecular target
RSK2
Online Access:https://doi.org/10.1002/cam4.3136

Internet

https://doi.org/10.1002/cam4.3136

Similar Items